Pricing

Five things for pharma marketers to know: Friday, January 12, 2018

Five things for pharma marketers to know: Friday, January 12, 2018

By

Pharma looks to Spark for pricing blueprint; Ipsen hires Amgen exec as CEO of North America; FDA could improve social-media approach, study finds

Five things for pharma marketers to know: Thursday, January 11, 2018

Five things for pharma marketers to know: Thursday, January 11, 2018

By

Novartis Oncology taps Pfizer exec as CEO; healthcare jobs become the largest source of U.S. employment; HHS nominee wary about drug-pricing negotiations

Taxpayers Need to Cough up the Cash to Keep Federal Agencies Afloat

Taxpayers Need to Cough up the Cash to Keep Federal Agencies Afloat

As we continue to debate the proper size and role of government in society, cast your eyes on recent polls by Gallup and Pew that found the majority of Americans felt their income tax was fair.

Five things for pharma marketers to know: Wednesday, January 3, 2018

Five things for pharma marketers to know: Wednesday, January 3, 2018

By

Utah Senator who backed Orphan Drug Act will not seek reelection; medicines more expensive in 2018; Spark's genetic therapy for rare blindness costs $850,000

Five things for pharma marketers to know: Tuesday, December 19, 2017

Five things for pharma marketers to know: Tuesday, December 19, 2017

By

Pharma industry spent $57 million on lobbying in 2016; Humana, private equity firms to buy Kindred for $4 billion; price of old glaucoma drug skyrockets

MM&M 2018 staff predictions: From gift bans to Google Assistant

MM&M 2018 staff predictions: From gift bans to Google Assistant

By

From gift bans to Google Assistant, POC to OPDP, MM&M staff members give their predictions on what to expect in healthcare marketing in 2018

Five things for pharma marketers to know: Thursday, December 14, 2017

Five things for pharma marketers to know: Thursday, December 14, 2017

By

Pharma R&D return on investment falls to eight-year low; FDA approves Pfizer's biosimilar to J&J's Remicade; Novartis to downsize generics business

Tax Bill Is Good News for Life Sciences and Marketing

Tax Bill Is Good News for Life Sciences and Marketing

Although it's a long way from the president's desk, the Tax Cut and Jobs Act of 2017 contains plenty of good news for the life sciences industry and its marketing partners.

Five things for pharma marketers to know: Tuesday, December 5, 2017

Five things for pharma marketers to know: Tuesday, December 5, 2017

By

Botox-like wrinkle-reducer shows positive results in trials; investors double down on fertility; few websites transparent about pricing, study finds

Five things for pharma marketers to know: Friday, December 1, 2017

Five things for pharma marketers to know: Friday, December 1, 2017

By

FDA approves first Apple Watch health accessory; medical charity shared data with pharma donors; FDA approves opioid-addiction treatment

Five things for pharma marketers to know: Wednesday, November 8, 2017

Five things for pharma marketers to know: Wednesday, November 8, 2017

By

FDA to change Risk Evaluation Mitigation Strategies to prevent delayed generic approvals; Ohio rejects drug-price measure; Aetna CEO wants to improve in-person pharmacy experience

Five things for pharma marketers to know: Wednesday, November 1, 2017

Five things for pharma marketers to know: Wednesday, November 1, 2017

By

Drug industry spends nearly $50 million to fight drug-price referendum; Novartis weighs sales of generic unit; ICER to evaluate all newly approved drugs

Five things for pharma marketers to know: Thursday, October 26, 2017

Five things for pharma marketers to know: Thursday, October 26, 2017

By

Non-profit challenges Gilead's Sovaldi patent; The Medicines Company to cut hundreds of jobs; Amgen ends R&D for experimental CETP drug

Five things for pharma marketers to know: Wednesday, October 25, 2017

Five things for pharma marketers to know: Wednesday, October 25, 2017

By

FDA develops resources about biosimilars for HCPs; Biogen negotiates royalties for experimental Alzheimer's drug; GSK Q3 sales driven by HIV, respiratory drugs

10 questions for PhRMA's CEO Stephen Ubl

10 questions for PhRMA's CEO Stephen Ubl

By

Trade group PhRMA's CEO talks about his first year in the job amid public outrage about price gouging.

Five things for pharma marketers to know: Wednesday, September 27, 2017

Five things for pharma marketers to know: Wednesday, September 27, 2017

By

AbbVie adds context to CEO's comments on drug pricing; Pandora makes a play for pharma ad dollars; shortages expected of drugs manufactured in Puerto Rico

Five things for pharma marketers to know: Tuesday, September 26, 2017

Five things for pharma marketers to know: Tuesday, September 26, 2017

By

Patient assistance nonprofit contacted in Aegerion probe; most heavily marketed drugs in Canada offer little therapeutic value; the FDA pans Duchenne drug

Five things for pharma marketers to know: Wednesday, September 13, 2017

Five things for pharma marketers to know: Wednesday, September 13, 2017

By

FDA closes pediatric study loophole; little evidence outcomes-based contracts are working; PBMs lobby against transparency efforts

Snubbing Intolerance: Frazier's Path Was Disengagement

Snubbing Intolerance: Frazier's Path Was Disengagement

By

Merck CEO Kenneth Frazier's exit from a presidential manufacturing council may go down as one of the most principled stands by the CEO of a major U.S. company, let alone a drugmaker.

Five things for pharma marketers to know: Thursday, August 31, 2017

Five things for pharma marketers to know: Thursday, August 31, 2017

By

Pfizer develops Minecraft version for kids with hemophilia; Lilly to resubmit baricitinib to the FDA; pricing expert says Novartis CAR-T value contract is 'progress'

Five things for pharma marketers to know: Wednesday, August 30, 2017

Five things for pharma marketers to know: Wednesday, August 30, 2017

By

Nonprofits receive FDA approval for Chagas drug; Gilead's buyout of Kite will put it back in pricing fray; most cancer patients don't receive fertility info

Five things for pharma marketers to know: Wednesday, August 23, 2017

Five things for pharma marketers to know: Wednesday, August 23, 2017

By

Doctors fret about price of Novartis' experimental CAR-T therapy; study finds digital pillboxes don't improve adherence; India awards Pfizer vaccine patent

Five things for pharma marketers to know: Friday, August 18, 2017

Five things for pharma marketers to know: Friday, August 18, 2017

By

Lawmakers to investigate pricing of MS drugs; Mylan will pay $465 million to resolve EpiPen allegations; the FDA approves Pfizer's new cancer drug

Study: Hiking the prices of heart drugs led to fewer sales

Study: Hiking the prices of heart drugs led to fewer sales

By

Prescription rates dramatically decreased following the price hikes of Valeant's Isuprel and Nitropress in 47 hospitals.

Five things for pharma marketers to know: Wednesday, August 16, 2017

Five things for pharma marketers to know: Wednesday, August 16, 2017

By

Gottlieb criticizes drugmakers for 'gaming the system' on generics; investors ignore Trump's pharma criticism; docs are more supportive of single payer

Frazier's call earns him praise, rare for a pharma CEO

Frazier's call earns him praise, rare for a pharma CEO

By

It's not often that pharmaceutical companies are held up as examples of morality or leadership to the general public.

Questions About Promotion Prompt Marketers to Develop Code of Ethics

Questions About Promotion Prompt Marketers to Develop Code of Ethics

That's why the Coalition for Healthcare Communication is focused on creating self-regulatory guidelines.

Biogen, Merck use predictive modeling to better negotiate value-based contracts

Biogen, Merck use predictive modeling to better negotiate value-based contracts

By

What's holding back value-based pricing deals from moving beyond the pilot phase?

Bill to allow imported drugs from Canada aims to create competition

Bill to allow imported drugs from Canada aims to create competition

By

The Congressional Budget Office says that Sanders' bill would save the U.S. federal government nearly $7 billion over the next decade.

On Shkreli, Here Are the Lessons for Pharma to Learn and Apply

On Shkreli, Here Are the Lessons for Pharma to Learn and Apply

Though Shkreli may soon slip from the public eye, separated from his Twitter account and prohibited from trading securities, pharma communicators must learn from these events.